Real-World Gestational Diabetes Screening: Problems with the Oral Glucose Tolerance Test in Rural and Remote Australia

Emma L. Jamieson 1,*, Erica P. Spry 2,3, Andrew B. Kirke 1, David N. Atkinson 3 and Julia V. Marley 2,3

1 The Rural Clinical School of Western Australia, The University of Western Australia, Bunbury 6233, Australia; andrew.kirke@rcswa.edu.au
2 Kimberley Aboriginal Medical Services, Broome 6725, Australia; research@kams.org.au (E.P.); julia.marley@rcswa.edu.au (J.V.M.)
3 The Rural Clinical School of Western Australia, The University of Western Australia, Broome 6725, Australia; david.atkinson@rcswa.edu.au
* Correspondence: emma.jamieson@rcswa.edu.au; Tel.: +61-8-9722-0510

Received: 7 October 2019; Accepted: 11 November 2019; Published: 14 November 2019

Abstract: Gestational diabetes mellitus (GDM) is the most common antenatal complication in Australia. All pregnant women are recommended for screening by 75 g oral glucose tolerance test (OGTT). As part of a study to improve screening, 694 women from 27 regional, rural and remote clinics were recruited from 2015–2018 into the Optimisation of Rural Clinical and Haematological Indicators for Diabetes in pregnancy (ORCHID) study. Most routine OGTT samples were analysed more than four hours post fasting collection (median 5.0 h, range 2.3 to 124 h), potentially reducing glucose levels due to glycolysis. In 2019, to assess pre-analytical plasma glucose (PG) instability over time, we evaluated alternative sample handling protocols in a sample of participants. Four extra samples were collected alongside routine room temperature (RT) fluoride-oxalate samples (FLOX RT); study FLOX RT; ice slurry (FLOX ICE); RT fluoride-citrate-EDTA (FC Mix), and RT lithium-heparin plasma separation tubes (PST). Time course glucose measurements were then used to estimate glycolysis from ORCHID participants who completed routine OGTT after 24 weeks gestation (n = 501). Adjusting for glycolysis using FLOX ICE measurements estimated 62% under-diagnosis of GDM (FLOX RT 10.8% v FLOX ICE 28.5% (95% CI, 20.8–29.5%), p < 0.001). FC Mix tubes provided excellent glucose stability but gave slightly higher results (Fasting PG: +0.20 ± 0.05 mmol/L). While providing a realistic alternative to the impractical FLOX ICE protocol, direct substitution of FC Mix tubes in clinical practice may require revision of GDM diagnostic thresholds.

Keywords: gestational diabetes; GDM; oral glucose tolerance test; OGTT; glycolysis

1. Introduction

Due to the high global incidence of gestational diabetes mellitus (GDM) and potential for improved perinatal outcome, the International Association of Diabetes in Pregnancy Study Groups (IADPSG) recommends all pregnant women, without pre-existing diabetes, be screened for hyperglycaemia by 75 g oral glucose tolerance test (OGTT) [1,2]. In 2008, the IADPSG convened a consensus panel of member organisations to review several studies that demonstrated a continuous linear association between mild maternal hyperglycaemia, measured by OGTT, and adverse perinatal outcomes [3–7]. In 2010, the IADPSG consensus panel derived new OGTT diagnostic cut-points for GDM based only on Hyperglycaemia and Adverse Pregnancy Outcomes (HAPO) study data.
HAPO data was selected due to the robust study design, including strict pre-analytical OGTT protocol, which was standardised across multiple international sites [2,3]. Fluoride has historically been used to stabilise glucose in OGTT samples; however, glycolysis is not inhibited over the first hour post-collection and takes four hours to completely inhibit glycolysis [8]. The World Health Organization (WHO) first recommended rapid plasma separation from fluoride collections in their Diabetes Mellitus 1985 study group report, in acknowledgement of delays in glycolytic inhibition [9]. To minimise glycolysis, the HAPO study pre-analytical OGTT protocol stipulated immediate immersion of fluoride-oxalate (FLOX) samples in ice-slurry or crushed-ice, prior to plasma separation [10,11]. This is impractical in most routine clinical and laboratory settings and has not been implemented in Australia; most laboratories batch transport FLOX samples without recommendation for storage on ice or for rapid plasma separation (Table A1).

Other countries use pragmatic alternatives to the HAPO protocol to address pre-analytical glucose instability. The American Diabetes Association (ADA) national guidelines recommend collection into tubes with an immediate glycolytic inhibitor, such as citrate, if delays of more than 30 min are anticipated [12]. Reiterated in diabetes guidelines across Europe, 2008 European Standards recommend combined fluoride-citrate tubes for immediate and long-term stabilisation of plasma glucose [13–16]. Rapid centrifugation of lithium-heparin plasma separation tubes (PST) is considered a gold-standard method to minimise glycolysis for research purposes [17].

The impact of glycolysis on GDM diagnosis can be significant. Daly et al. observed a 2.7-fold increase in GDM by HAPO protocol, compared to routine hospital procedures [18]. The group suggested GDM under-diagnosis was further compounded by longer delays to analysis for OGTT collected at external clinics (GDM incidence: 17.8% hospital clinic v 10.6% external clinic, 30 km from laboratory) [19]. Using a basic linear adjustment of retrospective data from a large Victorian regional centre, Song et al. also estimated that there would be a substantial increase in GDM if fluoride-citrate-EDTA (FC Mix) tubes were used instead of routine procedures (39.2% vs. 13.5% by standard procedures) [20]. However, they suggested that glycolysis had no clinical impact as they reported the same proportion of large-for-gestational-age (LGA) babies in the lower HAPO glucose categories.

Large distances and delays to laboratory analysis are common in rural and remote Australia. The prospective Optimisation of Rural Clinical and Haematological Indicators for Diabetes in pregnancy (ORCHID) study was conducted in regional, rural and remote Western Australian clinical settings. Only 50% of women complete screening for GDM by OGTT in these settings [21]. ORCHID aimed to investigate ways to improve screening for GDM and relied on OGTT collected using local clinical and laboratory protocols. As part of ORCHID we explored the potential impact of glycolysis and a pre-analytical protocol change on GDM diagnosis. This paper aims to describe a detailed analysis of glucose decline over time for fasting, 1-h and 2-h OGTT samples in FLOX tubes stored at room temperature. It also aims to model the potential impact of estimated glycolysis on GDM incidence in the ORCHID study cohort.

2. Materials and Methods

Setting: In Western Australia (WA), 21.3% of pregnant women reside regionally [22]. Maternity services are facilitated by public hospital maternity care, midwifery group practice care, community midwifery/shared care, general practitioner obstetric care or team midwifery care. Sample selection for the ORCHID study was biased to over-represent Aboriginal women to allow sub-cohort analysis of this high-risk group.

Data were collected by local health care providers from 9 January 2015 to 31 May 2018, at 27 sites in the Kimberley, Mid-West, Goldfields, Southwest and Great Southern regions of WA. The Modified Monash Model (MMM) was used to classify clinic location; for binary analysis remote clinics (MMM6 and MMM7) were classified as MMM ≥ 6.
Recruitment and data collection of the ORCHID cohort: Pregnant women presenting for their first antenatal visit at a participating site, aged 16 years or older, no documented pre-existing diabetes, and singleton pregnancy, were invited to take part. Maternal characteristics, including known risk factors for GDM, were recorded by antenatal care providers at recruitment and at time of routine OGTT after 24 weeks gestation. Birth outcomes were obtained from hospital discharge summaries and special care nursery discharge summaries.

Prospective ORCHID cohort OGTT and glucose measurement: Local clinical and laboratory procedures were relied on for 75 g OGTT collection, transport and laboratory analysis. Participants were classified as having GDM if one or more IADPSG 2010 glucose criteria were met [2]:

- Fasting plasma glucose ≥ 5.1 mmol/L
- 1-h plasma glucose ≥ 10.0 mmol/L
- 2-h plasma glucose ≥ 8.5 mmol/L

A survey of all ORCHID study sites revealed that local pathology specimen collection protocols did not use the same pre-analytical protocol as HAPO. All venous whole blood samples were collected into FLOX tubes (BD Biosciences, Australia) and batch sent to local pathology laboratories. Sample storage and transportation temperature varied by site (refrigerated or room temperature). Distances between study sites and laboratory ranged from 0.35 km by road to 650 km by air. Upon arrival at the pathology laboratory, plasma was separated for measurement of glucose by hexokinase method [23]. Time delay between collection and analysis was recorded for 424 OGTT; minimum delay by site was used when this data was missing (n = 77). A separate sub-cohort of seven participants from a remote clinic had paired FC Mix (Greiner Bio-One, Austria) collections alongside standard OGTT.

Recruitment of the OGTT time-course group: Pregnant women presenting for their routine 24–28 week OGTT at a metropolitan hospital, aged 16 years or older, no documented pre-existing diabetes and singleton pregnancy, were invited to take part.

Time-course OGTT and adjustment algorithms: To generate algorithms to adjust ORCHID cohort OGTT results for estimated glycolysis due to delay to analysis, 12 pregnant women in a metropolitan hospital setting had additional samples collected alongside their routine OGTT from 24 May 2019 to 5 July 2019 (Figure 1). Eleven women completed OGTT. Complete tube fill was ensured for all samples:

- FLOXRT protocol: FLOX tube (5 mL BD Biosciences, Australia) stored at room temperature. Aliquots collected at 0.25 h, 0.5 h, 0.75 h, 1 h, 1.5 h, 2 h, 2.5 h, 3 h, 3.5 h, and 4 h.
- FLOXICE protocol: FLOX tube (2 mL BD Biosciences, Australia) placed immediately in ice-slurry. Aliquots collected at 0.25 h, 0.5 h, 0.75 h, and 1 h.
- FC Mix protocol: FC Mix tube (3 mL) stored at room temperature. Aliquots collected at 0.25 h, 0.5 h, 0.75 h, 1 h, and 4 h.
- PST protocol: PST (3 mL BD Biosciences, Australia), centrifuged within 5 min of collection at 1300×g for 5 min, and stored at room temperature. Separated plasma fraction remained in the collection tube for the entire experiment.

Following four hours at room temperature, FLOXRT, FC Mix, and PST tubes from six participants were also refrigerated overnight for 24 h plasma glucose analysis. All whole blood aliquots (300 µL) were centrifuged at 1300×g for 5 min and 100 µL of plasma removed for plasma glucose analysis.

Plasma glucose aliquots were immediately analysed by glucose oxidase, hydrogen peroxide method (Ortho-Clinical Diagnostics, Vitros 5600 Integrated System; median time to completion of analysis was 8.2 min, IQR 6.2 to 10.2 min). Inter-assay CV was < 2.17% and haemolysis, icterus, and turbidity index for all samples were below local interference thresholds. Upon arrival in the same laboratory, plasma from the standard OGTT samples was separated for measurement of glucose by the same method.
Figure 1. Flowchart for prospective ORCHID cohort participation and OGTT time course group participation, documenting completion of recommended screening for hyperglycaemia in pregnancy by 75 g oral glucose tolerance test (OGTT). ORCHID = Optimisation of Rural Clinical and Haematological Indicators for Diabetes in pregnancy; GDM = gestational diabetes mellitus; PG = plasma glucose; FLOX$^\text{ICE}$ protocol = fluoride-oxalate (FLOX) samples stored immediately on ice; FLOX$^\text{RT}$ protocol = FLOX samples stored at room temperature (RT); FC Mix protocol = fluoride-citrate-EDTA samples stored at RT; PST protocol = lithium-heparin plasma separation tubes centrifuged within 5 min of collection at 1300x g for 5 min and stored at RT. *GDM diagnosed if one or more International Association for Diabetes in Pregnancy Study Groups (IADPSG) 2010 glucose criteria were met: FPG ≥ 5.1 mmol/L; 1-h PG ≥ 10.0 mmol/L; 2-h PG ≥ 8.5 mmol/L.

Baseline FLOX$^\text{ICE}$ glucose was calculated as mean FLOX$^\text{ICE}$ glucose from plasma separated < 1 h post-collection based on ice stabilisation assessment (Table A2). Baseline FC Mix glucose was calculated as mean FC Mix glucose from plasma separated ≤ 4 h. Beta coefficients were calculated by linear regression for plasma glucose, delay and delay-squared to estimate baseline FLOX$^\text{ICE}$ or baseline FC Mix (Table A3). A separate estimate for GDM by FC Mix protocol was calculated for participants within MMM remoteness categories 2 and 3 using the basic linear algorithm used by Song et al.: plasma glucose multiplied by 1.113 for fasting samples; 1.081 for 1-h samples and 1.061 for 2-h samples (Table A4) [20]. IADPSG 2010 criteria were applied to algorithm-adjusted ORCHID cohort OGTT results to obtain adjusted GDM incidence.

Statistical analysis: Study data were collected and managed using secure REDCap electronic data capture tools hosted at The University of Western Australia [24]. All analyses were performed with Stata, version 14 (Statacorp, College Station, United States of America). For LGA infants (birth weight greater than 90th centile), birth weight centiles were calculated using the Global bulk centile calculator, GROW v8.0.1 (Perinatal Institute, Birmingham, United Kingdom), adjusting for gestational age, maternal height, maternal weight at first antenatal visit, parity, ethnicity, and infant sex. Adjustment for maternal weight was made within body mass index (BMI, maternal weight/height$^2$ (kg/m$^2$)) limits of 18.5–30 kg/m$^2$ only. Differences in characteristics between groups were compared using t-tests for continuous data and $\chi^2$ tests for categorical data, with the exception of differences in remoteness classification, which was compared by Cuzick non-parametric test for trend across ordered groups. Differences in glucose concentrations between paired OGTT samples were compared using
t-tests. Differences between standard and adjusted GDM incidence were compared using McNemar’s test. Error for adjusted GDM incidence for FLOXICE and FC Mix algorithms was calculated from proportional 95% CI obtained from validation of algorithms in time-course participants. Low and high 95% CI values were used to adjust IADPSG fasting, 1-h and 2-h plasma glucose cut-points to obtain a 95% CI for adjusted GDM incidence. A p-value of less than 0.05 was defined as statistically significant.

Ethics approval: Ethics approval was obtained from the Western Australian Aboriginal Health Ethics Committee (2014-007) and WA Country Health Service Research Ethics Committee (2014-16). The Kimberley Aboriginal Health Planning Forum Research Subcommittee supported this project.

3. Results

Six hundred and ninety-four women were enrolled in ORCHID. Six hundred ORCHID participants delivered their babies after 30 weeks gestation. This represented 2.7% of 22,513 births to rural WA women over the period of the ORCHID Study (WA Midwives Notification System, data extract date: 4 December 2018).

Eleven ORCHID participants with GDM detected by OGTT between 6- and 12-weeks gestation were excluded from analysis. Of the remaining 589 ORCHID participants recommended for OGTT completion after 24 weeks gestation, only 85.1% completed an OGTT despite amenability at recruitment (Figure 1). Participants of high-risk Aboriginal or Torres Strait Islander ethnicity, hereafter referred to as Aboriginal, were younger (26.0 ± 5.2 years vs. other ethnicity 30.2 ± 5.3 years, p < 0.001) more likely to have a family history of type 2 diabetes (98/229, 42.8% vs. other ethnicity 83/360, 23.1%, p < 0.001) and more likely to decline or not complete the OGTT (Table 1). Aboriginal women who did complete the OGTT, did so at a later gestational age (28.8 ± 2.4 weeks vs. other ethnicity 27.3 ± 1.5 weeks, p < 0.001). Aboriginal women also commenced OGTT later in the morning (median (IQR) time of fasting plasma glucose collection: Aboriginal 9:17 a.m. (8:48 a.m. to 9:45 a.m.) vs. other ethnicity; 8:35 a.m. (8:10 a.m. to 9:10 a.m.), p < 0.001).

GDM incidence after 24 weeks gestation was lower than expected in this high-risk cohort (GDM: 10.8%; 54/501 complete OGTT). Almost half of ORCHID fasting plasma glucose samples fell within the lowest of seven glucose categories defined in HAPO (2.5–4.1 mmol/L: 44.9%, 225/501 vs. HAPO 17.4%, 4043/23,231, p < 0.001). After exclusion of 49 participants who were managed for GDM, incidence of LGA reached 10% at HAPO fasting glucose category one (10.7%, 23/192); 1-h glucose category two (5.9–7.3 mmol/L: 10.0%, 17/170) and 2-h glucose category two (5.1–6.0 mmol/L: 13.2% 21/159). Most ORCHID OGTT samples were stored at room temperature (92%, 461/501) and had long delay to laboratory analysis (median time to analysis for fasting plasma glucose: 5.0 h; range 2.3 to 124 h).
were not analysed on the day of collection.

- Plasma glucose,
- Stability (mean di ICE samples held at room temperature for four hours, compared to baseline FLOX

| Characteristic | Total Cohort n (%) | OGTT Complete n = 501 (85.1%) | OGTT not Done or Incomplete n = 88 (14.9%) | p-Value |
|----------------|--------------------|-------------------------------|-----------------------------------------------|---------|
| Maternal characteristics |                     |                               |                                               |         |
| Age (years)       | 589 (100%)         | 28.8 ± 5.7                    | 27.1 ± 5.0                                    | 0.008   |
| Ethnicity         |                    |                               |                                               |         |
| Non-Indigenous    | 324 (55.0%)        | 300 (92.6%)                   | 24 (7.4%)                                     | < 0.001 |
| Aboriginal and Torres Strait Islander | 229 (38.9%) | 169 (73.8%)                   | 60 (26.2%)                                    |         |
| Other high-risk ethnicity § | 36 (6.1%) | 32 (88.9%)                    | 4 (11.1%)                                     |         |
| BMI after 24 weeks (kg/m²) | 589 (100%) | 28.5 ± 6.1                    | 28.5 ± 7.2                                    | 0.92    |
| BMI category ¶ |                    |                               |                                               | 0.28    |
| Normal or underweight (< 28.4) | 330 (56.0%) | 281 (85.2%)                   | 49 (14.8%)                                    |         |
| Overweight (28.5–32.9) | 130 (22.1%) | 115 (88.5%)                   | 15 (11.5%)                                    |         |
| Obese (≥ 33.0) | 129 (21.9%) | 105 (81.4%)                   | 24 (18.6%)                                    |         |
| Parity (prior delivery ≥ 20 weeks) ≥ 1 at enrolment | 401 (68.1%) | 336 (83.8%)                   | 65 (16.2%)                                    | 0.21    |
| Family history of diabetes § | 181 (30.7%) | 146 (80.7%)                   | 35 (19.3%)                                    | 0.046   |
| Any antenatal smoking | 162 (27.5%) | 116 (71.6%)                   | 46 (28.4%)                                    | < 0.001 |
| Antenatal urinary tract infection | 30 (5.1%) | 26 (86.7%)                    | 4 (13.3%)                                     | 0.80    |
| Previous caesarean delivery ¶ | 70 (17.5%) | 62 (88.6%)                    | 8 (11.4%)                                     | 0.23    |
| Length of gestation at first antenatal presentation (weeks) | 589 (100%) | 9.8 ± 5.8                     | 11.2 ± 7.1                                    | 0.057   |
| Remote classification of health service |            |                               |                                               | 0.220   |
| MMM2             | 50 (8.5%)          | 48 (96.0%)                    | 2 (4.0%)                                      |         |
| MMM3             | 383 (65.0%)        | 320 (83.6%)                   | 63 (16.4%)                                    |         |
| MMM6             | 78 (13.2%)         | 72 (92.3%)                    | 6 (7.7%)                                      |         |
| MMM7             | 78 (13.2%)         | 61 (78.2%)                    | 17 (21.8%)                                    |         |
| Newborn characteristics |                  |                               |                                               |         |
| Gestational age at delivery (weeks) | 589 (100%) | 39.2 ± 1.5                    | 38.8 ± 1.6                                    | 0.015   |
| Birthweight (g)   | 589 (100%)         | 3458 ± 351                    | 3221 ± 511                                    | < 0.001 |
| Length (cm) § | 586 (99.4%) | 50.6 ± 2.7                    | 49.3 ± 2.5                                    | < 0.001 |
| Head circumference (cm) ¶ | 587 (99.7%) | 34.6 ± 1.6                    | 34.2 ± 1.5                                    | 0.025   |
| Sex—Male | 303 (51.4%) | 266 (87.8%)                   | 37 (12.2%)                                    | 0.056   |

ORCHID = Optimisation of Rural Clinical and Haematological Indicators for Diabetes in pregnancy study; OGTT = 75 g oral glucose tolerance test; BMI = body mass index; MMM = Modified Monash Model. Data include women eligible for screening after 24 weeks gestation; Data are mean ± standard deviation for continuous variables. For categorical variables, data are number (%) of cohort for total cohort or number (%) of total with characteristic for OGTT group. Two-sided t-test p-value reported for comparison between groups for continuous data. Pearson Chi-square test p-value reported for comparison between groups for categorical data, with the exception of differences in remoteness classification, which was compared by Cuzick non-parametric test for trend across ordered groups. § Other high-risk ethnicity includes African (n = 3), Asian (n = 8), Indian (n = 4), Middle-Eastern (n = 3), Maori (n = 13), and Pacific-Islander (n = 5) women. ¶ BMI, maternal weight in kilograms divided by the square of maternal height in meters, calculated after 24 weeks gestation. BMI categorised according to World Health Organization criteria as adjusted by Hyperglycaemia and Pregnancy Outcomes Study Group to account for maternal weight gain by 24 weeks gestation. † Family history of diabetes includes women with a first-degree relative with type 1 or type 2 diabetes or history of GDM. ¶ Previous caesarean delivery includes only women of parity (prior delivery ≥ 20 weeks) ≥ 1 at enrolment. Data only available for 498 participants with complete OGTT. † Head circumference only available for 499 participants with complete OGTT.

In the time-course analysis, plasma glucose measurements were significantly lower in FLOXRT samples held at room temperature for four hours, compared to baseline FLOXICE protocol (mean difference ± SD (mmol/L): fasting plasma glucose: −0.43 ± 0.07, p < 0.001; 1-h plasma glucose: −0.48 ± 0.17, p < 0.001; 2-h plasma glucose: −0.44 ± 0.19, p < 0.001, Figure 2).

PST, centrifuged immediately, gave similar glucose values to baseline plasma glucose by FLOXICE protocol (Figure 2). However, significant loss of glucose was observed in PST samples at 24 h (−0.22 mmol/L ± 0.16 vs. PST at 5 min, p < 0.001). Only FC Mix tubes provided 24 h plasma glucose stability (mean difference ± SD (mmol/L) at 24 h compared to baseline FC Mix measurement: fasting plasma glucose, −0.03 ± 0.07, p = 0.398; 1-h plasma glucose, −0.02 ± 0.09, p = 0.674; 2-h plasma glucose, −0.02 ± 0.05, p = 0.427, Figure 2). Notably, 25.6% (34/133) of OGTT from remote ORCHID study sites were not analysed on the day of collection.
was observed in this metropolitan hospital setting (median delay 3.1 h, range 2.4–3.7 h). In the other samples, compared to fasting. Despite this variability, the FLOXICE and FC Mix algorithms showed high validity across all three OGTT time-points when used to adjust standard OGTT results from time-course participants (Tables 2 and 3). Minimal variation in delay to analysis from fasting collection was observed in this metropolitan hospital setting (median delay 3.1 h, range 2.4–3.7 h). In the other paired-sample analysis conducted at a remote clinic, adjusted standard OGTT glucose concentrations were comparable to those obtained from FC Mix tubes; however, a slight and insignificant overestimate of glycolysis at the 2-h sample was observed (mean (95% CI: absolute (mmol/L) and proportional (%)) difference in adjusted plasma glucose compared to FC Mix plasma glucose: fasting plasma glucose, 0.04 (−0.01 to 0.09) −0.1% to 2.0%), p = 0.13; 1-h plasma glucose, 0.05 (−0.06 to 0.17), −0.69% to 2.34%), p = 0.37; 2-h plasma glucose, 0.17 (−0.03 to 0.37) −0.9% to 5.5%), p = 0.14).
Table 2. Unadjusted and FLOX\textsuperscript{ICE} algorithm adjusted plasma glucose (mmol/L) measured by standard laboratory procedures compared to FLOX\textsuperscript{ICE} protocol in ORCHID time-course participants.

| OGGT Sample | OGGT by FLOX\textsuperscript{ICE} Protocol | OGGT by Standard Procedures | Standard OGGT Adjusted by FLOX\textsuperscript{ICE} Algorithm |
|-------------|---------------------------------|-----------------------------|-------------------------------------------------|
|             | PG | Delay to Analysis (h) | PG | PG Difference v FLOX\textsuperscript{ICE} Protocol | PG | PG Difference v FLOX\textsuperscript{ICE} Protocol |
| Fasting     | 4.9 ± 0.47 | 3.0 ± 0.4 | 4.5 ± 0.51 *** | −0.42 [−0.47 to −0.37] | 0.02 [−0.04 to 0.07] |
|             | 6.5 ± 1.76 | 2.0 ± 0.4 | 6.1 ± 1.67 *** | −0.38 [−0.47 to −0.28] | 0.01 [−0.12 to 0.10] |
| 2-h         | 5.8 ± 1.25 | 1.1 ± 0.4 | 5.6 ± 1.12 **  | −0.26 [−0.42 to −0.10] | −0.02 [−0.18 to 0.13] |

Table 3. Unadjusted and adjusted FC Mix algorithm plasma glucose (mmol/L) measured by standard laboratory procedures compared to FC Mix protocol in ORCHID time-course participants.

| OGGT Sample | OGGT by FC Mix Protocol | OGGT by Standard Procedures | Standard OGGT Adjusted by FC Mix Protocol |
|-------------|-------------------------|-----------------------------|----------------------------------------|
|             | PG | Delay to Analysis (h) | PG | PG Difference v FC Mix Protocol | PG | PG Difference vs. FC Mix Protocol |
| Fasting     | 5.1 ± 0.47 | 3.0 ± 0.4 | 4.5 ± 0.51 *** | −0.62 [−0.67 to −0.56] | 5.1 ± 0.50 | −0.01 [−0.06 to 0.05] |
| 1-h         | 6.8 ± 1.88 | 2.0 ± 0.4 | 6.1 ± 1.67 *** | −0.63 [−0.84 to −0.43] | 6.8 ± 1.74 | −0.01 [−0.21 to 0.18] |
| 2-h         | 6.0 ± 1.28 | 1.1 ± 0.4 | 5.6 ± 1.12 **  | −0.49 [−0.73 to −0.26] | 6.0 ± 1.28 | −0.03 [−0.20 to 0.14] |

FC Mix = Fluoride-citrate-EDTA samples stored at room temperature; ORCHID = Optimisation of Rural Clinical and Haematological Indicators for Diabetes in pregnancy study; PG = plasma glucose; ORCHID = 75 g oral glucose tolerance test. Data include 12 participants with paired FC Mix samples collected at the same time as their standard OGGT (1-h and 2-h samples, n = 11). Data are mean (± SD) for delay to analysis (h) and PG (mmol/L) and mean (95% CI absolute (mmol/L) and proportional (%)) for difference in PG compared to samples processed by FLOX\textsuperscript{ICE} protocol. PG by standard procedures, unadjusted and algorithm adjusted, compared to FLOX\textsuperscript{ICE} protocol using students paired t-test. p-value < 0.01 ***, < 0.001 ***, FC Mix protocol: FC Mix samples stored at room temperature. Five aliquots, taken at 15 min, 30 min, and 45 min (< 1 h post-collection) were centrifuged for plasma separation and immediate PG measurement. FLOX\textsuperscript{ICE} PG data is the mean glucose over the five sample aliquots. OGGT by standard procedure for site: samples collected into FLOX tubes and stored and transported to laboratory at room temperature. Time of analysis of standard procedure samples was recorded and delay to analysis calculated from time of collection. Standard OGGT results were adjusted by linear regression β-coefficients for PG + delay-to-analysis + delay-to-analysis\textsuperscript{2} + constant, estimated for FLOX\textsuperscript{ICE} protocol PG using FLOX\textsuperscript{ICE} time-course data (Table A2).

Adjustment to account for reduced glycolysis under HAPO study (FLOX\textsuperscript{ICE}) conditions revealed significant under-diagnosis of GDM in the ORCHID cohort due to standard pre-analytical protocols (GDM: standard FLOX, 10.8% vs. FLOX\textsuperscript{ICE} 28.5% (95% CI, 20.8–29.9%, p < 0.001). FC Mix protocol substantially increased GDM incidence to 45.3% (95% CI, 35.7–55.1%) of the cohort screened (Table 4). Increases in GDM incidence by both FLOX\textsuperscript{ICE} and FC Mix protocol were predominantly due to increased detection of hyperglycaemia in fasting OGGT samples (FLOX\textsuperscript{ICE} estimate: 81.1% with GDM diagnosed by fasting plasma glucose; FC Mix estimate: 86.3% with GDM diagnosed by fasting plasma glucose). Application of the linear algorithm for ORCHID participants whose OGGT was collected in larger regional sites underestimated GDM incidence compared to our non-linear adjustment (32.1% by linear algorithm vs. 50.5% by FC Mix algorithm, p < 0.001, Table A4).
Table 4. Unadjusted and adjusted OGTT, by FLOX\textsuperscript{ICE}, or FC Mix algorithm, in ORCHID prospective cohort participants and proportion with GDM, stratified by ethnicity.

|                  | Mean Glucose ± SD (mmol/L) | n (%) Above Diagnostic Threshold at Each OGTT Sample | Cumulative n (%) Diagnosed with GDM |
|------------------|----------------------------|-----------------------------------------------------|--------------------------------------|
|                  | Aboriginal (n = 169)    | Other Ethnicity (n = 332)                          | p-Value                               |
| **Unadjusted OGTT** |                             |                                                     |                                      |
| Fasting PG       | 4.2 ± 0.49                | 4.3 ± 0.40                                         | 0.005                                |
| 1-h PG           | 7.1 ± 1.74                | 6.9 ± 1.72                                         | 0.208                                |
| 2-h PG           | 6.1 ± 1.63                | 5.9 ± 1.39                                         | 0.245                                |
|                  | 9 (5.3%)                  | 13 (3.9%)                                          | 0.467                                |
|                  | 10 (5.9%)                 | 18 (5.4%)                                          | 0.819                                |
|                  | 13 (7.7%)                 | 18 (5.4%)                                          | 0.319                                |
|                  | 9 (5.3%)                  | 13 (3.9%)                                          |                                      |
|                  | 14 (8.3%)                 | 26 (7.8%)                                          |                                      |
|                  | 20 (11.8%)                | 34 (10.2%)                                         |                                      |
| **FLOX\textsuperscript{ICE} adjusted OGTT** |                             |                                                     |                                      |
| Fasting PG       | 4.7 ± 0.47                | 4.8 ± 0.41                                         | 0.022                                |
| 1-h PG           | 7.6 ± 1.67                | 7.4 ± 1.69                                         | 0.114                                |
| 2-h PG           | 6.4 ± 1.52                | 6.2 ± 1.32                                         | 0.126                                |
|                  | 30 (17.8%)                | 86 (25.9%)                                         | 0.041                                |
|                  | 14 (8.3%)                 | 23 (6.9%)                                          | 0.583                                |
|                  | 16 (9.5%)                 | 25 (7.5%)                                          | 0.454                                |
|                  | 30 (17.8%)                | 86 (25.9%)                                         |                                      |
|                  | 33 (19.5%)                | 96 (28.9%)                                         |                                      |
|                  | 39 (23.1%)                | 104 (31.3%)                                        |                                      |
| **FC Mix adjusted OGTT** |                             |                                                     |                                      |
| Fasting PG       | 4.9 ± 0.46                | 5.0 ± 0.41                                         | 0.017                                |
| 1-h PG           | 8.0 ± 1.77                | 7.7 ± 1.80                                         | 0.110                                |
| 2-h PG           | 6.8 ± 1.76                | 6.5 ± 1.52                                         | 0.111                                |
|                  | 49 (29.0%)                | 147 (44.3%)                                        | 0.001                                |
|                  | 17 (10.1%)                | 37 (11.1%)                                         | 0.711                                |
|                  | 24 (14.2%)                | 32 (9.6%)                                          | 0.125                                |
|                  | 49 (29.0%)                | 147 (44.3%)                                        |                                      |
|                  | 54 (32.0%)                | 159 (47.9%)                                        |                                      |
|                  | 61 (36.1%)                | 166 (50.0%)                                        |                                      |

\textbf{ORCHID} = Optimisation of Rural Clinical and Haematological Indicators for Diabetes in pregnancy study; OGTT = 75 g oral glucose tolerance test; PG = plasma glucose; FLOX\textsuperscript{ICE} = fluoride-oxalate (FLOX) samples stored immediately on ice; FC Mix = fluoride-citrate-EDTA samples stored at room temperature. Data include 501 participants with complete OGTT women eligible for screening after 24 weeks gestation; Data are mean glucose ± SD (mmol/L) for ethnic group or number (%) of ethnic group with OGTT outcome. Two-sided \textit{t}-test \textit{p}-value reported for comparison between ethnic group for continuous data. Pearson Chi-square test \textit{p}-value reported for comparison between ethnic group for categorical data. OGTT results were adjusted by linear regression \(\beta\)-coefficients for PG + delay-to-analysis + delay-to-analysis\(^2\) + constant for estimated FLOX\textsuperscript{ICE} protocol PG or FC Mix protocol PG from ORCHID time-course participants.
Fasting plasma glucose was significantly lower in Aboriginal participants compared to the rest of the ORCHID cohort, even after adjustment. Consequently, the proportion of Aboriginal participants estimated to have GDM by adjusted fasting plasma glucose alone was also lower, as was overall estimated GDM incidence by FC Mix protocol (Table 4).

4. Discussion

We estimate 62% of regional, rural and remote Western Australian women with GDM are not diagnosed by 24–28 week OGTT due to a sample processing issue. Whilst plasma glucose instability has been raised as an important consideration by some groups [18,25], the extent to which glycolysis impacts GDM diagnosis for women in diverse rural and remote Australian settings has not been previously characterised. As observed in other cohorts, glycolysis had the largest impact on GDM diagnosis by fasting plasma glucose [18,26]. This is unsurprising considering batched fasting OGTT samples have the longest delay to analysis and narrowest standard deviation: 0.5 mmol/L in ORCHID and 0.4 mmol/L in HAPO. This rendered the small average HAPO FLOXICE adjustment of 0.44 mmol/L ± 0.1 in fasting glucose highly significant, and was 3.7 times larger than seasonal variation reported in the Brisbane and Newcastle HAPO study sites (+0.12 mmol/L) [27].

However, the HAPO FLOXICE protocol is impractical in most settings. If we are to acknowledge the impact glycolysis has on identification of women for GDM management, suitable alternate protocols to stabilise glucose must be explored. Plasma glucose from PST closely matched HAPO FLOXICE values over four hours, however the PST protocol has several disadvantages requiring consideration: necessity for immediate access to a centrifuge in collection area; increase in sample-handling burden on clinic staff (in our setting this would predominately be midwives), and potential for glycolysis to continue unabated if tubes are not centrifuged immediately and for sufficient time. In addition, poor long-term stability of glucose, also observed in other stability assessments [28] would render the PST protocol an unsatisfactory alternative for remote locations, where 25.6% were not processed on the same day they were collected.

In contrast, fluoride-citrate-EDTA (FC Mix) tubes ensured both short and long-term glucose stability and substitution of FC Mix tubes into clinical practice would not require additional changes to clinic collection protocols. However, revision of diagnostic criteria may be warranted as FC Mix plasma glucose values were, on average, 0.2 mmol/L higher than those obtained by research grade methodology. Reports of citrate or fluoride-citrate glycolytic inhibition compared to research grade methodology in the literature are inconsistent, ranging from no observed difference in plasma glucose to +0.34 mmol/L higher (reviewed by Carey et al.) [29]. These differences are potentially related to method variations for participant selection, research grade anticoagulant/inhibitor, cooling, timing of plasma separation or use of liquid versus lyophilised citrate buffer. For direct comparison of GDM by IADPSG criteria in our study, we recruited pregnant women at routine OGTT, strictly followed the HAPO study protocol and selected lyophilised FC Mix tubes in order to avoid potential issues with dilution factor corrections. The small but significantly higher glucose estimates by FC Mix protocol had the largest impact on GDM diagnoses by adjusted fasting plasma glucose and resulted in 1.8-fold higher estimation of GDM compared to FLOXICE protocol.

As Song et al. used retrospective data, the delay to analysis was unknown; the authors applied a basic linear adjustment, assuming a uniform delay of 3.6 h from fasting collection, 2.4 h from 1-h collection and 1.6 h from 2-h collection [20]. However, delays to analysis in our cohort were larger and varied between sites, even within geographically similar sites to the Victorian cohort, explaining the underestimation of GDM by linear algorithm compared to our non-linear adjustment. The authors also speculated that the FLOXIC protocol was likely not adhered to by HAPO study sites, using poor adherence to time restrictions for processing cord-blood samples as an indication. They suggested that a protocol change to minimise glycolysis is not warranted based on the lack of a shift towards higher rates of LGA babies in lower HAPO glucose categories in their cohort. By contrast, we observed rates of LGA above 10% at the two lowest glucose categories. We also showed that incubation on ice stabilised
glucose concentrations in FLOX tubes by 1 h post-collection, therefore it is unlikely that further delay to analysis for HAPO study OGTT samples would have lowered glucose measurements (Table A2). The Victorian cohort represented a low-risk, predominantly Caucasian population, with significantly lower BMI and birth weight outcomes compared to the ORCHID cohort, which may explain some of the differences in LGA incidence distribution between cohorts (BMI: Song et al. 27.7 ± 0.2 vs. ORCHID 28.5 ± 0.27, p = 0.026; birth weight: Song et al. 3376g ± 502 vs. 3458 ± 531, p = 0.003) [20]. The authors also reported that plasma was separated in all OGTT samples prior to transportation to laboratory. This would have reduced glycolysis significantly; however, this is not the procedure used in Western Australia and would be difficult to implement where OGTTs are not conducted in laboratory settings.

Increases in GDM by FLOXICE or FC Mix protocol appeared attenuated in Aboriginal women, due to lower fasting glucose compared to the rest of the ORCHID cohort. This difference may be due to sampling bias; Aboriginal women were younger and more likely to decline OGTT and may therefore not be representative of the underlying population. Another explanation could be increased foetal glucose steal activity, as Aboriginal women tended to complete OGTT later in gestation. Aboriginal participants also tended to commence OGTT later in the morning. Established diurnal trends for declining fasting glucose throughout the morning, even after adjustment for fasting duration, may have contributed to the lower fasting glucose observed in Aboriginal participants [30,31]. Therefore, whilst our estimates suggest the impact of implementation of FC Mix tubes on GDM diagnosis may not be as great in Aboriginal women who do complete an OGTT, caution is advised when interpreting differences in this ethnic group.

It is a study limitation that our GDM estimates for the ORCHID cohort are based on algorithmic adjustment; however, a direct comparison of standard and alternate OGTT protocols to HAPO FLOXICE protocol was not feasible in our rural and remote setting. We acknowledge that the 1-h and 2-h algorithms were not as robust as the fasting, due to greater inter-individual variation of glycolysis in the post-load samples. This is an additional source of imprecision, and a simple, standard adjustment of routine OGTT results to correct for glycolysis would likely add to measurement uncertainty. However, as the fasting algorithms were robust, and the pattern of predominant diagnosis by fasting sample held true for both FLOXICE and FC Mix adjustments, it is likely our FC Mix GDM estimates will prove to be accurate when tested prospectively. Furthermore, by standardising pre-analytical processes for glucose, screening by fasting plasma glucose alone, as suggested by other groups, may become a viable option to improve screening coverage in our population with poor OGTT completion [21,32].

The HAPO study did not document time to plasma separation. As FLOXICE plasma glucose was stabilised by 45 min, we calculated mean plasma glucose from FLOXICE protocol 15 min, 30 min, and 45 min samples as an estimate of plasma glucose by HAPO protocol. However, other groups have demonstrated that the largest drop in glucose following ice-immersion occurs within the first 15 min post-collection [33,34]. Despite attaining core tube temperatures of 5 °C at 3 min post-ice-immersion, the reported inter-individual glycolytic rate at 15 min is highly variable (range: no change to −0.29 mmol/L, n = 7). Our study did not include a time-0 FLOX measurement. This may have biased baseline FLOXICE calculations towards lower glucose concentrations compared to HAPO, had immediate centrifugation been achieved.

Due to the geographical diversity of participating sites, it is likely that temperatures prior to and during sample transportation varied. This information, which could have a significant impact on glycolysis, is unknown. In addition, the error for GDM estimates by adjusted OGTT is calculated from time-course participant data. As our adjustment algorithms were also based on time-course data, it is possible that this error is underestimated. When the FC Mix algorithm was applied to the remote cohort with paired FC Mix tube collections, algorithmic adjustment was biased towards a small over-estimation of glucose at the 2-h sample.

Another study limitation is that the error around adjusted GDM incidence does not include analytical error. OGTT samples were measured at local laboratories state-wide, with pathology
provider based on clinician choice. All laboratories were National Association of Testing Authorities, Australia (NATA) accredited, however the magnitude of imprecision and inter-laboratory bias for glucose measurements at each laboratory is unknown. ADA 2011 recommendations for glucose measurement are for imprecision ≤ 2.9%, and bias ≤ 2.2%, allowing a total analytical error (TAE) of ≤ 6.9% [12]. TAE for glucose, even within allowable limits, can have a significant impact on GDM incidence. Agarwal et al. applied the allowable TAE to IADPSG criteria to obtain a 95% confidence interval for each diagnostic threshold: fasting plasma glucose, 4.7–5.5 mmol/L; 1-h plasma glucose, 9.3–10.7 mmol/L; and 2-h plasma glucose, 7.9–9.1 mmol/L [35]. This translated to a 0.5- to 1.7-fold change in GDM incidence in a United Arab Emirates cohort, depending on threshold used.

For appropriate interpretation of diagnostic results, clinicians must be aware of measurement uncertainty, including biological, pre-analytical, and laboratory variation. However, it is not a requirement to report estimates of measurement uncertainty with pathology results. The Royal College of Pathologists of Australasia and the Australasian Association of Clinical Biochemists encourage clinicians to contact their pathology provider to ascertain measurement uncertainty for each assay [36,37]. Laboratories will only report TAE, without acknowledgment of sources of pre-analytical error. For samples at the diagnostic fasting threshold for GDM, the 4 h drop in glucose due to glycolysis alone exceeds the allowable TAE.

Whilst site and laboratory differences could be considered a study limitation, they also highlight the difficulties of consistent implementation of research protocols in real world settings and strengthen the argument for pre-analytical standardisation. It should also be noted that centralisation of laboratory measurement for research is not without problems. Several months of OGTT data from HAPO were algorithmically adjusted following discovery of bias between the central laboratory and all other site laboratories [10]. The bias was related to an inconsistent batch of analytical reagents.

The introduction of the IADPSG criteria raised concerns about the likelihood of overwhelming numbers of women diagnosed with GDM and the burden on antenatal care services that would follow. Figures from this study and others suggest this has not happened. We believe, in our cohort of rural women, a significant number who should be recognised as having GDM by the IADPSG criteria are being missed due to processing issues. The biggest impact of addressing this issue will be felt on the women diagnosed on fasting blood glucose. A significant proportion of these will be managed with diet, exercise, and timed delivery at the end of pregnancy. A smaller proportion will require greater clinical input, insulin, or other hypoglycaemic medication and more specialist intervention. Overall the major impact of standardising pre-analytical processes is likely to be the need for a more comprehensive education program about blood sugar control for all pregnant women, as greater numbers will be picked up in the lower risk end of the spectrum. The true impact of the IADPSG 2010 criteria will also become visible with the removal of the effect of pre-analytical glycolysis in GDM screening.

5. Conclusions

This study evaluated the impact of glycolysis on GDM incidence in a high risk regional, rural and remote Australian cohort and the potential impact of alternate pre-analytical protocols aimed at minimising glycolysis. Poor stabilisation of glucose in OGTT samples likely results in significant under-diagnosis of GDM in these settings, where large delays to laboratory analysis are unavoidable. Screening outcomes are inconsistent due to wide variation in analytical delay, and a simple linear adjustment of OGTT results by clinicians is not suitable. Due to the small window available for testing and intervention, accurate diagnosis of GDM is crucial to avert adverse outcomes. Pre-analytical standardisation of glycolysis can be achieved by use of FC Mix tubes. The benefits of improved GDM detection and management in high-risk women from regional, rural, and remote settings should be considered when debating the use of these tubes. Validation of new fasting plasma glucose diagnostic criteria for use with FC Mix collections is warranted to avert unnecessary increased burden for GDM management.
Author Contributions: All persons who meet authorship criteria are listed as authors, and all authors certify that they have participated sufficiently in the work to take public responsibility for the content, including participation in the concept, design, analysis, writing, or revision of the manuscript. The specific contributions made by each author are indicated below: Conceptualization, E.L.J., J.V.M., D.N.A., and A.B.K.; Methodology, E.L.J., J.V.M., E.P.S., A.B.K., and D.N.A.; Validation, E.L.J. and J.V.M.; Formal analysis, E.L.J., J.V.M., A.B.K., and D.N.A.; Investigation, E.L.J., E.P.S., J.V.M., A.B.K., and D.N.A.; Resources, E.L.J., E.P.S., and J.V.M.; Data curation, E.L.J. and E.P.S.; Writing—original draft preparation E.L.J. and J.V.M.; Writing—review and editing, E.L.J., J.V.M., A.B.K., D.N.A., and E.P.S.; Supervision, J.V.M.; Project administration, E.L.J., E.P.S., and J.V.M.; Funding acquisition, J.V.M, D.N.A., A.B.K., E.L.J., and E.P.S.

Funding: This research was funded by Diabetes Australia, Y17G-MARJ; Lishman Health Foundation, PG63000695 and The University of Western Australia, Rural Clinical School of WA multi-site grant, PG63000694. E.L.J. was funded by Australian Government Research Training Program stipend.

Acknowledgments: We acknowledge contributions by all regional ORCHID study Clinical Investigators at study design and during participant recruitment: Emma Griffiths; Sarah Moore; Cindy Porter; Carly Roxburgh; Sally Singleton; and Kylie Sterry. We acknowledge all project managers, antenatal care providers and administrative staff from all participating clinics and all ORCHID study participants. We acknowledge the assistance of staff from the state pathology laboratory, Pathwest.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Appendix A

Table A1. Fasting duration, preferred specimen type, and storage and transport recommendations for OGTT samples processed by NATA accredited Australian pathology facilities.

| Pathology Laboratory                      | Location                        | Fasting Duration          | Preferred Specimen | Storage/Transport         |
|-------------------------------------------|---------------------------------|----------------------------|---------------------|---------------------------|
| Abbott Pathology Laboratory               | SA Statewide                    | 10–12 h (max 16 h)        | fluoride-oxalate    | No recommendation         |
| ACT Pathology                             | ACT Territory wide               | 8–12 h                    | fluoride-oxalate    | No recommendation         |
| Alfred Health                             | VIC Statewide                   | > 8 h (no max)            | fluoride-oxalate    | Transport at RT           |
| Austin Pathology                          | VIC Statewide                   | 8–12 h                    | fluoride-oxalate    | No recommendation         |
| Australian Clinical Labs                  | WA Statewide                    | No recommendation          | SST or fluoride-oxalate | No recommendation         |
| Australian Clinical Labs                  | SA Statewide                    | 10–14 h                   | fluoride-oxalate or capillary if difficult bleed | No recommendation |
| Australian Clinical Labs                  | NSW Statewide, VIC Statewide & NT Territory wide | 12–14 h | fluoride-oxalate or capillary if difficult bleed | No recommendation |
| Cabrini Health                            | VIC Metropolitan                | 8–12 h                    | No recommendation   | No recommendation         |
| Capital Pathology                         | NSW Statewide & ACT territory wide | No recommendation          | fluoride-oxalate    | No recommendation         |
| Clinipath                                 | WA Statewide                    | 10–16 h                   | fluoride-oxalate    | No recommendation         |
| Dorevitch Pathology                       | VIC Statewide                   | 8–10 h                    | fluoride-oxalate    | No recommendation         |
| Douglass Hanly Moir Pathology             | NSW Statewide                   | 8–12 h                    | fluoride-oxalate    | RT                        |
| Eastern Health Pathology                  | VIC Metropolitan                | Overnight (max 16 h)      | fluoride-oxalate    | No recommendation         |
| Goulburn Valley Health                    | VIC Regional                    | 10–14 h                   | fluoride-oxalate    | Standard transport         |
| Hobart Pathology                          | TAS Metropolitan                | 8–15 h                    | fluoride-oxalate    | No recommendation         |
|                                          |                                 |                           |                     |                           |
| Pathology Laboratory                          | Location                | Fasting Duration | Preferred Specimen | Storage/Transport                                                                 |
|---------------------------------------------|-------------------------|------------------|--------------------|-----------------------------------------------------------------------------------|
| Launceston Pathology                        | TAS Metropolitan        | 8–15 h           | fluoride-oxalate    | No recommendation                                                                 |
| Laverty Laboratory                          | NSW & ACT Statewide     | 8–14 h           | fluoride-oxalate    | Do not centrifuge; Refrigerate                                                       |
| Melbourne Pathology                         | VIC Statewide           | 8–12 h           | fluoride-oxalate    | No recommendation                                                                 |
| Monash Pathology                            | VIC Metropolitan        | 8–16 h           | fluoride-oxalate    | No recommendation                                                                 |
| NSW Health Pathology—North                  | NSW Statewide           | 10 h (no min or max) | fluoride-oxalate    | No recommendation for storage; transport 2–8 °C                                     |
| NSW Health Pathology—SEALS                  | NSW South East          | 8–10 h           | fluoride-oxalate/EDTA | Refrigerate                                                                        |
| NSW Health Pathology—SSWPS                  | NSW Metropolitan        | From 10 pm (no specific duration) | Not specified | If delayed separate serum and refrigerate; transport at RT |
| Pathology Queensland                        | QLD Statewide           | Overnight (no specific duration) | fluoride-oxalate    | No storage recommendation; transport cool                                           |
| Pathology South                             | TAS Metropolitan        | 8–16 h           | fluoride-oxalate/EDTA | No recommendation                                                                 |
| Pathwest                                    | WA Statewide            | 10–16 h          | fluoride-oxalate    | No recommendation                                                                 |
| QML Pathology                               | QLD Statewide           | 8–16 h           | SST or fluoride-oxalate | No recommendation                                                                 |
| Royal Children’s Hospital Laboratory Services | VIC Metropolitan        | 10 h (no min or max) | fluoride-oxalate    | No recommendation                                                                 |
| SA Pathology                                | SA Statewide            | 10–16 h          | fluoride-oxalate    | No storage recommendation; transport < 25 °C                                        |
| Southern IML                                | NSW Statewide           | 10–12 h          | SST                 | No recommendation                                                                 |
| St Vincent’s Pathology                      | VIC Metropolitan        | 10 h (no min or max) | fluoride-oxalate    | No recommendation                                                                 |
| Sullivan Nicolaides Pathology               | QLD Statewide           | 8–16 h           | SST                 | No recommendation                                                                 |
| Sydpath                                     | NSW Metropolitan        | From 10 pm (no specific duration) | fluoride-oxalate    | No recommendation                                                                 |
| TML Pathology                               | TAS Metropolitan        | 8–12 h           | Not specified       | No recommendation                                                                 |
| Western Diagnostic                          | WA Statewide & NT Territory wide | No recommendation | fluoride-oxalate    | No recommendation                                                                 |
| Women’s and Children’s Pathology, The Royal Children’s Hospital | VIC Metropolitan | 10 h | fluoride-oxalate or SST if centrifuged < 3 h if fluoride-oxalate not collected | No recommendation |

OGTT = oral glucose tolerance test; RT = room temperature; fluoride-oxalate = sodium fluoride/potassium oxalate vacutainer blood collection tube; SST = serum separation vacutainer blood collection tube; °C, degrees Celsius; h = hours; min = minimum; max = maximum; ASAP = as soon as possible; Australian States and Territories: ACT = Australian Capital Territory; NSW = New South Wales; NT = Northern Territory; QLD = Queensland; SA = South Australia; TAS = Tasmania; VIC = Victoria; WA = Western Australia. The National Association of Testing Authorities (NATA) ‘Find Accredited Facilities’ page was searched to identify accredited facilities within Australia, URL: https://www.nata.com.au/accredited-facility using keyword search term: ‘human pathology’. The website for each facility was located and OGTT patient information sheets and OGTT laboratory test guides were investigated for OGTT specific recommendations for fasting duration, specimen type, and storage and transport recommendations.
Table A2. Mean plasma glucose in timed aliquots from FLOX<sub>ICE</sub> protocol samples from ORCHID time-course participants.

| OGTT Sample | Timed Aliquot Plasma Glucose (mmol/L) | 15 min | 30 min | 45 min | 1 h |
|-------------|--------------------------------------|--------|--------|--------|-----|
|             |                                      | 4.9 ± 0.49 ** | 4.9 ± 0.46 * | 4.9 ± 0.47 | 4.9 ± 0.45 |
| Fasting     |                                      | 6.5 ± 1.75 * | 6.6 ± 1.85 ** | 6.5 ± 1.76 | 6.4 ± 1.75 |
| 1-h         |                                      | 5.8 ± 1.24 | 5.8 ± 1.25 | 5.8 ± 1.26 | 5.8 ± 1.28 |

OGTT = 75 g oral glucose tolerance test. FLOX<sub>ICE</sub> = fluoride-oxalate samples stored immediately in crushed ice. Data are mean ± SD plasma glucose (mmol/L). Differences in plasma glucose between 1 h timed aliquot and earlier aliquots were compared by students paired t-test; * p < 0.05; ** p < 0.01. FLOX<sub>ICE</sub> protocol: 300 µL aliquots taken at regular time intervals, centrifuged at 1300×g for 5 min and 100 µL of plasma separated for glucose analysis.

Table A3. Beta coefficients for FLOX<sub>ICE</sub> and FC mix algorithms.

|                   | Plasma Glucose | Delay | Delay<sup>2</sup> | Constant |
|-------------------|----------------|-------|------------------|----------|
| **FLOX<sub>ICE</sub> algorithm** |                |       |                  |          |
| Fasting PG        | 0.999          | 0.108 | −0.004           | 0.125    |
|                   | (0.966–1.032)  | (0.093–0.122) | (−0.004–−0.003) | (−0.034–0.283) |
| p < 0.001         | p < 0.001      | p < 0.001 | p = 0.122       |          |
|                   | 0.981          | 0.107 | −0.004           | 0.279    |
| 1-h PG            | 0.961–1.000    | 0.074–0.139 | (−0.005–−0.002) | (0.140–0.419) |
| p < 0.001         | p < 0.001      | p < 0.001 | p < 0.001       |          |
|                   | 0.949          | 0.091 | −0.003           | 0.426    |
| 2-h PG            | 0.919–0.979    | 0.055–0.127 | (−0.002)       | (0.243–0.610) |
| p < 0.001         | p < 0.001      | p < 0.001 | p < 0.001       |          |

|                   |                |       |                  |          |
| **FC mix algorithm** |                |       |                  |          |
| Fasting PG        | 0.986          | 0.106 | −0.004           | 0.386    |
|                   | (0.953–1.019)  | (0.091–0.121) | (−0.004–−0.003) | (0.227–0.545) |
| p < 0.001         | p < 0.001      | p < 0.001 | p < 0.001       |          |
|                   | 1.043          | 0.112 | −0.004           | 0.146    |
| 1-h PG            | (1.015–1.071)  | (0.066–0.158) | (−0.006–−0.002) | (−0.055–0.347) |
| p < 0.001         | p < 0.001      | p < 0.001 | p < 0.001       | p = 0.154 |
|                   | 1.098          | 0.105 | −0.004           | −0.182   |
| 2-h PG            | (1.075–1.120)  | (0.078–0.132) | (−0.005–−0.003) | (−0.321–(−0.044) |
| p < 0.001         | p < 0.001      | p < 0.001 | p < 0.001       | p = 0.01 |

FLOX = fluoride-oxalate; FC Mix = fluoride-citrate-EDTA. To generate algorithms to adjust OGTT results for estimated glycolysis due to delay to analysis, 12 participants in a hospital setting had paired samples collected alongside their standard OGTT (1-h and 2-h samples, n = 11): FLOX<sub>RT</sub> protocol: FLOX tube (5 mL BD Biosciences, Australia) stored at room temperature (RT). Aliquots collected at 0.25 h, 0.5 h, 0.75 h, 1 h, 1.5 h, 2 h, 2.5 h, 3 h, 3.5 h, and 4 h. FLOX<sub>ICE</sub> protocol: FLOX tube (2 mL BD Biosciences, Australia) placed immediately in ice-slurry. Aliquots collected at 0.25 h, 0.5 h, 0.75 h, 1 h, and 4 h. FC Mix protocol: FC Mix tube (3 mL Greiner Bio-One, Austria) stored at RT. Aliquots collected at 0.25 h, 0.5 h, 0.75 h, 1 h, and 4 h. Following 4 h incubation, FLOX<sub>RT</sub>, FC Mix and PST tubes from six participants were refrigerated overnight for 24 h PG analysis. Whole blood aliquots (300 µL) were centrifuged at 1300×g for 5 min and 100 µL of plasma removed for plasma glucose (PG) analysis. Baseline FLOX<sub>ICE</sub> glucose was calculated as mean FLOX<sub>ICE</sub> glucose from plasma separated <1 h post-collection. Baseline FC Mix glucose was calculated as mean FC Mix glucose from plasma separated ≤4 h. Beta coefficients were calculated by linear regression for FLOX<sub>RT</sub> PG, delay, and delay-squared to estimate baseline FLOX<sub>ICE</sub> or baseline FC Mix.
Table A4. Plasma glucose (mmol/L) for and cumulative GDM incidence by unadjusted OGTT and adjusted by the basic linear adjustment used by Song et al. or FC Mix algorithm in regional ORCHID participants who attended clinics within remoteness classification MMM2 and MMM3.

| OGGT Sample | OGGT by Standard Procedures | Standard OGTT Adjusted by Song et al. Algorithm | Standard OGTT Adjusted by FC Mix Algorithm |
|-------------|----------------------------|-----------------------------------------------|------------------------------------------|
|             | Median Delay to Analysis (h) | PG | Cumulative GDM Diagnosis | PG | PG Difference vs. Standard Protocol | Cumulative GDM Diagnosis | PG | PG Difference vs. Standard Protocol | Cumulative GDM Diagnosis |
| Fasting     | 4.9 (3.6–6.2)                | 4.33 ± 0.44 | 19 (5.2) | 4.82 ± 0.49 | 0.49 ± 0.06 | 93 (25.3) | 5.04 ± 0.43 | 0.71 ± 0.12 | 167 (45.4) |
| 1-h         | 3.8 (2.5–5.1)                | 7.03 ± 1.79 | 34 (9.2) | 7.60 ± 1.93 | 0.57 ± 0.15 | 109 (29.6) | 7.80 ± 1.85 | 0.78 ± 0.15 | 179 (48.6) |
| 2-h         | 2.9 (1.5–4.2)                | 5.99 ± 1.50 | 43 (11.7) | 6.35 ± 1.59 | 0.37 ± 0.09 | 118 (32.1) | 6.62 ± 1.62 | 0.64 ± 0.20 | 186 (50.5) |

OGTT = 75 g oral glucose tolerance test; FC Mix = fluoride-oxalate-EDTA; ORCHID = Optimisation of Rural Clinical and Haematological Indicators for Diabetes in pregnancy study; MMM = Modified Monash Model. Data are median (interquartile range) in hours for delay to analysis or mean ± SD for plasma glucose or difference in plasma glucose for ORCHID study participants who attended clinics within MMM remoteness classification categories 2 or 3 and completed OGTT (n = 368). These clinics were selected due to similarities with the region serviced by Ballarat Health Services (MMM category 2–5). The ORCHID study did not have sites within MMM 4 or 5 remoteness classification categories.
References

1. Karuranga, S.; Fernandes, J.; Huang, Y.; Malanda, B. IDF Diabetes Atlas, 8th ed.; International Diabetes Federation: Brussels, Belgium, 2017; pp. 26–65.
2. Metzger, B.E.; Gabbe, S.G.; Persson, B.; Buchanan, T.A.; Catalano, P.A.; Damm, P.; Dyer, A.R.; Leiva, A.; Hod, M.; Kitzmiller, J.L.; et al. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care 2010, 33, 676–682. [CrossRef] [PubMed]
3. Metzger, B.E.; Lowe, L.P.; Dyer, A.R.; Trumble, E.R.; Chaovarindr, U.; Coustan, D.R.; Hadden, D.R.; McCance, D.R.; Hod, M.; McIntyre, H.D.; et al. Hyperglycemia and adverse pregnancy outcomes. N. Engl. J. Med. 2008, 358, 1991–2002. [CrossRef] [PubMed]
4. Pettitt, D.J.; Knowler, W.C.; Baird, H.R.; Bennett, P.H. Gestational diabetes: Infant and maternal complications of pregnancy in relation to third-trimester glucose tolerance in the Pima Indians. Diabetes Care 1980, 3, 458–464. [CrossRef]
5. Clausen, T.D.; Mathiesen, E.R.; Hansen, T.; Pedersen, O.; Jensen, D.M.; Lauenborg, J.; Damm, P. High prevalence of type 2 diabetes and pre-diabetes in adult offspring of women with gestational diabetes mellitus or type 1 diabetes: The role of intrauterine hyperglycemia. Diabetes Care 2008, 31, 340–346. [CrossRef]
6. Jensen, D.M.; Damm, P.; Sorensen, B.; Molsted-Pedersen, L.; Westergaard, J.G.; Klebe, J.; Beck-Nielsen, H. Clinical impact of mild carbohydrate intolerance in pregnancy: A study of 2904 nondiabetic Danish women with risk factors for gestational diabetes mellitus. Am. J. Obstet. Gynecol. 2001, 185, 413–419. [CrossRef]
7. Sacks, D.A.; Greenspoon, J.S.; Abu-Fadil, S.; Henry, H.M.; Wolde-Tsadik, G.; Yao, J.F. Toward universal criteria for gestational diabetes: The 75-gram glucose tolerance test in pregnancy. Am. J. Obstet. Gynecol. 1995, 172, 607–614. [CrossRef]
8. Chan, A.Y.; Swaminathan, R.; Cockram, C.S. Effectiveness of sodium fluoride as a preservative of glucose in blood. Clin. Chem. 1989, 35, 315–317.
9. Diabetes Mellitus: Report of A WHO Study Group [meeting held in Geneva from 11 to 16 February 1985]; World Health Organization: Geneva, Switzerland, 1985.
10. Nesbitt, G.S.; Smye, M.; Sheridan, B.; Lappin, T.R.; Trimble, E.R. Integration of local and central laboratory functions in a worldwide multicentre study: Experience from the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study. Clin. Trials 2006, 3, 397–407. [PubMed]
11. Hapo Study Cooperative Research Group. The Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study. Int. J. Gynaecol. Obstet. 2002, 78, 69–77. [CrossRef]
12. Sacks, D.B.; Arnold, M.; Bakris, G.L.; Bruns, D.E.; Horvath, A.R.; Kirkman, M.S.; Lemmark, A.; Metzger, B.E.; Nathan, D.M.; Clinical, B.; et al. National Academy of Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Diabetes Care 2011, 34, 61–99. [CrossRef] [PubMed]
13. Tolonen, H.; Koponen, P.; Arornaa, A.; Conti, S.; Graff-Iversen, S.; Gretvedt, L.; Kanieff, M.; Mindell, J.; Naturen, S.; Primattega, P.; et al. Recommendations for the Health Examination Surveys in Europe for the Feasibility of A European Health Examination Survey (FEHES) Project, B21; National Public Health Institute: Helsinki, Finland, 2008; pp. 99–100.
14. Kleinwechter, H.; Schafer-Graf, U.; Buhrer, C.; Hoesli, I.; Kainer, F.; Kautzky-Willer, A.; Pawlowski, B.; Schunck, K.; Somville, T.; Sorger, M. Gestational Diabetes Mellitus (GDM) Diagnosis, Therapy and Follow-Up Care Practice Guideline of the German Diabetes Association (DDG) and the German Association for Gynaecology and Obstetrics (DGGG). Exp. Clin. Endocrinol. Diabetes 2014, 122, 395–405. [CrossRef] [PubMed]
15. Carta, M.; Mosca, A.; Lapolla, A.; Testa, R. Society Italiana patologia Clinica 2015 recommendations for oral glucose tolerance testing (OGTT). Biochim. Clin. 2015, 39, 135–140.
16. Eriksson-Boija, E.; Nordin, G. Swedish National Quality Goals for Measurement of Glucose: Guidance for the Laboratory; Equalis: Uppsala, Sweden, 2015; pp. 1–10.
17. Chan, H.; Lunt, H.; Thompson, H.; Heenan, H.F.; Frampton, C.M.; Florkowski, C.M. Plasma glucose measurement in diabetes: Impact and implications of variations in sample collection procedures with a focus on the first hour after sample collection. Clin. Chem. Lab. Med. 2014, 52, 1061–1068. [CrossRef] [PubMed]
18. Daly, N.; Flynn, I.; Carroll, C.; Farren, M.; McKeating, A.; Turner, M.J. Impact of Implementing Preanalytical Laboratory Standards on the Diagnosis of Gestational Diabetes Mellitus: A Prospective Observational Study. *Clin. Chem.* 2016, 62, 387–391. [CrossRef] [PubMed]

19. Stapleton, M.; Daly, N.; O’Kelly, R.; Turner, M.J. Time and temperature affect glycolysis in blood samples regardless of fluoride-based preservatives: A potential underestimation of diabetes. *Ann. Clin. Biochem.* 2017, 54, 671–676. [CrossRef]

20. Song, D.; Lia, M.; Hurley, J.C. Recommended pre-analytical plasma glucose sampling methodology may distort gestational diabetes mellitus prevalence: Implications for diagnostic thresholds. *Diabet. Med.* 2019, 11, 11. [CrossRef]

21. Kirke, A.B.; Atkinson, D.; Moore, S.; Sterry, K.; Singleton, S.; Roxburgh, C.; Parrish, K.; Porter, C.; Marley, J.V. Diabetes screening in pregnancy failing women in rural Western Australia: An audit of oral glucose tolerance test completion rates. *Aust. J. Rural Health* 2019. [CrossRef]

22. Jennings, B.; Joyce, A.; Pierce, A. *Western Australia’s Mothers and Babies, 2014: 32nd Annual Report of the Western Australian Midwives’ Notification System*; Department of Health, Western Australia: East Perth, Australia, 2018.

23. Coburn, H.J.; Carroll, J.J. Improved manual and automated colorimetric determination of serum glucose, with use of hexokinase and glucose-6-phosphate dehydrogenase. *Clin. Chem.* 1973, 19, 127–130.

24. Harris, P.A.; Taylor, R.; Thielke, R.; Payne, J.; Gonzalez, N.; Conde, J.G. Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support. *J. Biomed. Inf.* 2009, 42, 377–381. [CrossRef]

25. Gambino, R. Sodium fluoride: An ineffective inhibitor of glycolysis. *Ann. Clin. Biochem.* 2013, 50, 3–5. [CrossRef] [PubMed]

26. Daly, N.; Stapleton, M.; O’Kelly, R.; Kinsley, B.; Daly, S.; Turner, M.J. The role of preanalytical glycolysis in the diagnosis of gestational diabetes mellitus in obese women. *Am. J. Obstet. Gynecol.* 2015, 213, 84.e1–84.e5. [CrossRef] [PubMed]

27. Shen, E.X.; Moses, R.G.; Oats, J.N.N.; Lowe, J.; Mcintyre, H.D. Seasonality, temperature and pregnancy oral glucose tolerance test results in Australia. *BMC Pregnancy Childbirth* 2019, 19, 263. [CrossRef] [PubMed]

28. Brandhorst, G.; Engelmayer, J.; Gotze, S.; Oellerich, M.; von Ahsen, N. Pre-analytical effects of different lithium heparin plasma separation tubes in the routine clinical chemistry laboratory. *Clin. Chem. Lab. Med.* 2011, 49, 1473–1477. [CrossRef] [PubMed]

29. Carey, R.; Lunt, H.; Heenan, H.F.; Frampton, C.M.; Florkowski, C.M. Collection tubes containing citrate stabiliser over-estimate plasma glucose, when compared to other samples undergoing immediate plasma separation. *Clin. Biochem.* 2016, 49, 1406–1411. [CrossRef]

30. Desoye, G.; Nolan, C.J. The fetal glucose steal: An underappreciated phenomenon in diabetic pregnancy. *Diabetologia* 2016, 59, 1089–1094. [CrossRef]

31. Troisi, R.J.; Cowie, C.C.; Harris, M.I. Diurnal Variation in Fasting Plasma GlucoseImplications for Diagnosis of Diabetes in Patients Examined in the Afternoon. *JAMA* 2000, 284, 3157–3159. [CrossRef]

32. Agarwal, M.M. Gestational diabetes mellitus screening: With fasting plasma glucose. *World J. Diabetes* 2016, 7, 279–289. [CrossRef]

33. van den Berg, S.A.; Thelen, M.H.; Salden, L.P.; van Thiel, S.W.; Boonen, K.J. It takes acid, rather than ice, to freeze glucose. *Sci. Rep.* 2015, 5, 8875. [CrossRef]

34. Mikesh, L.M.; Bruns, D.E. Stabilization of glucose in blood specimens: Mechanism of delay in fluoride inhibition of glycolysis. *Clin. Chem.* 2008, 54, 930–932. [CrossRef]

35. Agarwal, M.M.; Dhatt, G.S.; Othman, Y. Gestational diabetes mellitus prevalence: Effect of the laboratory analytical variation. *Diabetes Res. Clin. Pract.* 2015, 109, 493–499. [CrossRef]

36. Badrick, T.; Stewart, P. Measurement Uncertainty. In *A Joint Initiative of Australian Doctor and the Royal College of Pathologists of Australasia; Flecknoe-Brown, S., Ed.; Cirrus Media: Chatswood, Australia, 2015*. [CrossRef]

37. White, G.H.; Farrance, I. Uncertainty of measurement in quantitative medical testing: A laboratory implementation guide by the AACC Uncertainty of Measurement Working Group. *Clin. Biochem. Rev.* 2004, 25, S1–S24. [PubMed]

© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).